Visco Carlo, Canal Fabio, Parolini Claudia, Andreoli Annalisa, Ambrosetti Achille, Krampera Mauro, Lestani Maurizio, Pizzolo Giovanni, Chilosi Marco
Department of Hematology, Ospedale S. Bortolo, Vicenza, Italy.
Haematologica. 2006 May;91(5):687-90.
Immunohistochemically detected over-expression of P53-related protein (P53+++) and absence of P21(waf1) expression (P21-) correspond to loss of function of the P53-gene in diffuse large B-cell lymphoma (DLBCL) patients. Using immunohistochemistry we examined 80 patients with DLBCL and found that 23% had the P53+++/P21- phenotype while 51% had a germinal center (GC) pattern. Both the P53+++/P21- phenotype and the non-GC pattern were associated with inferior outcome. Notably, the prognostic power of the P53+++/P21- phenotype was restricted to patients with a GC pattern, without effect on outcome of patients with a non-GC phenotype. Our results show that immunohistochemistry can parallel gene expression profiling in addressing clinical variability of DLBCL patients.
免疫组织化学检测发现，弥漫性大B细胞淋巴瘤（DLBCL）患者中P53相关蛋白过表达（P53+++）且P21（waf1）表达缺失（P21-）与P53基因功能丧失相对应。我们运用免疫组织化学方法检查了80例DLBCL患者，发现23%具有P53+++/P21-表型，而51%具有生发中心（GC）模式。P53+++/P21-表型和非GC模式均与较差的预后相关。值得注意的是，P53+++/P21-表型的预后价值仅限于具有GC模式的患者，对非GC表型患者的预后无影响。我们的结果表明，免疫组织化学在解决DLBCL患者临床变异性方面可与基因表达谱分析相媲美。
